116 related articles for article (PubMed ID: 17576594)
1. Tumor specificity and in vivo targeting of an antibody against exon 9 deleted E-cadherin in gastric cancer.
Lee HJ; Lee HS; Hur K; Kim WH; Yanagihara K; Becker KF; Lee KU; Yang HK
J Cancer Res Clin Oncol; 2007 Dec; 133(12):987-94. PubMed ID: 17576594
[TBL] [Abstract][Full Text] [Related]
2. [Novel mutation-specific monoclonal E-cadherin antibodies make possible allele differentiation at the protein level in tumors].
Becker I; Becker KF; Kremmer E; Eulitz M; Handschuh G; Höfler H
Verh Dtsch Ges Pathol; 1999; 83():233-9. PubMed ID: 10714216
[TBL] [Abstract][Full Text] [Related]
3. Analysis of E-cadherin in diffuse-type gastric cancer using a mutation-specific monoclonal antibody.
Becker KF; Kremmer E; Eulitz M; Becker I; Handschuh G; Schuhmacher C; Müller W; Gabbert HE; Ochiai A; Hirohashi S; Höfler H
Am J Pathol; 1999 Dec; 155(6):1803-9. PubMed ID: 10595908
[TBL] [Abstract][Full Text] [Related]
4. Highly specific tumor binding of a 213Bi-labeled monoclonal antibody against mutant E-cadherin suggests its usefulness for locoregional alpha-radioimmunotherapy of diffuse-type gastric cancer.
Senekowitsch-Schmidtke R; Schuhmacher C; Becker KF; Nikula TK; Seidl C; Becker I; Miederer M; Apostolidis C; Adam C; Huber R; Kremmer E; Fischer K; Schwaiger M
Cancer Res; 2001 Apr; 61(7):2804-8. PubMed ID: 11306447
[TBL] [Abstract][Full Text] [Related]
5. Functional allelic loss detected at the protein level in archival human tumours using allele-specific E-cadherin monoclonal antibodies.
Becker KF; Kremmer E; Eulitz M; Schulz S; Mages J; Handschuh G; Wheelock MJ; Cleton-Jansen AM; Höfler H; Becker I
J Pathol; 2002 Aug; 197(5):567-74. PubMed ID: 12210074
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the radiotoxicity of two alpha-particle-emitting immunoconjugates, terbium-149 and bismuth-213, directed against a tumor-specific, exon 9 deleted (d9) E-cadherin adhesion protein.
Miederer M; Seidl C; Beyer GJ; Charlton DE; Vranjes-Duric S; Comor JJ; Huber R; Nikula T; Apostolidis C; Schuhmacher C; Becker KF; Senekowitsch-Schmidtke R
Radiat Res; 2003 May; 159(5):612-20. PubMed ID: 12710872
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a mutant E-cadherin protein encoded by a mutant gene frequently seen in diffuse-type human gastric carcinoma.
Fukudome Y; Yanagihara K; Takeichi M; Ito F; Shibamoto S
Int J Cancer; 2000 Nov; 88(4):579-83. PubMed ID: 11058874
[TBL] [Abstract][Full Text] [Related]
8. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas.
Becker KF; Atkinson MJ; Reich U; Becker I; Nekarda H; Siewert JR; Höfler H
Cancer Res; 1994 Jul; 54(14):3845-52. PubMed ID: 8033105
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of the E-cadherin gene in sporadic diffuse-type gastric cancer.
Ascaño JJ; Frierson H; Moskaluk CA; Harper JC; Roviello F; Jackson CE; El-Rifai W; Vindigni C; Tosi P; Powell SM
Mod Pathol; 2001 Oct; 14(10):942-9. PubMed ID: 11598162
[TBL] [Abstract][Full Text] [Related]
10. Relationship between E-cadherin gene mutation and p53 gene mutation, p53 accumulation, Bcl-2 expression and Ki-67 staining in diffuse-type gastric carcinoma.
Fricke E; Keller G; Becker I; Rosivatz E; Schott C; Plaschke S; Rudelius M; Hermannstädter C; Busch R; Höfler H; Becker KF; Luber B
Int J Cancer; 2003 Mar; 104(1):60-5. PubMed ID: 12532420
[TBL] [Abstract][Full Text] [Related]
11. Fractionated locoregional low-dose radioimmunotherapy improves survival in a mouse model of diffuse-type gastric cancer using a 213Bi-conjugated monoclonal antibody.
Bloechl S; Beck R; Seidl C; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7070s-7074s. PubMed ID: 16203804
[TBL] [Abstract][Full Text] [Related]
12. E-cadherin expression in sporadic gastric cancer from Mexico: exon 8 and 9 deletions are infrequent events associated with poor survival.
Gamboa-Dominguez A; Dominguez-Fonseca C; Chavarri-Guerra Y; Vargas R; Reyes-Gutierrez E; Green D; Quintanilla-Martinez L; Luber B; Busch R; Becker KF; Becker I; Höfler H; Fend F
Hum Pathol; 2005 Jan; 36(1):29-35. PubMed ID: 15712179
[TBL] [Abstract][Full Text] [Related]
13. Tumour-associated E-cadherin mutations alter cellular morphology, decrease cellular adhesion and increase cellular motility.
Handschuh G; Candidus S; Luber B; Reich U; Schott C; Oswald S; Becke H; Hutzler P; Birchmeier W; Höfler H; Becker KF
Oncogene; 1999 Jul; 18(30):4301-12. PubMed ID: 10439038
[TBL] [Abstract][Full Text] [Related]
14. Locoregional alpha-radioimmunotherapy of intraperitoneal tumor cell dissemination using a tumor-specific monoclonal antibody.
Huber R; Seidl C; Schmid E; Seidenschwang S; Becker KF; Schuhmacher C; Apostolidis C; Nikula T; Kremmer E; Schwaiger M; Senekowitsch-Schmidtke R
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3922S-8S. PubMed ID: 14506190
[TBL] [Abstract][Full Text] [Related]
15. Arsenic sulfide inhibits cell migration and invasion of gastric cancer in vitro and in vivo.
Zhang L; Kim S; Ding W; Tong Y; Zhang X; Pan M; Chen S
Drug Des Devel Ther; 2015; 9():5579-90. PubMed ID: 26487802
[TBL] [Abstract][Full Text] [Related]
16. Rapid detection of mutated E-cadherin in peritoneal lavage specimens from patients with diffuse-type gastric carcinoma.
Schuhmacher C; Becker KF; Reich U; Schenk U; Mueller J; Siewert JR; Höfler H
Diagn Mol Pathol; 1999 Jun; 8(2):66-70. PubMed ID: 10475380
[TBL] [Abstract][Full Text] [Related]
17. [Correlation of E-cadherin hypermethylation to tumorigenesis and development of gastric cancer].
Liu WT; Jiao HL; Yang YL; Wang D; Zhang WM
Ai Zheng; 2007 Nov; 26(11):1199-203. PubMed ID: 17991318
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer.
Rosivatz E; Becker I; Specht K; Fricke E; Luber B; Busch R; Höfler H; Becker KF
Am J Pathol; 2002 Nov; 161(5):1881-91. PubMed ID: 12414534
[TBL] [Abstract][Full Text] [Related]
19. Combined evaluation of mucin antigen and E-cadherin expression may help select patients with gastric cancer suitable for minimally invasive therapy.
Tanaka M; Kitajima Y; Sato S; Miyazaki K
Br J Surg; 2003 Jan; 90(1):95-101. PubMed ID: 12520583
[TBL] [Abstract][Full Text] [Related]
20. C-Type Lectin-Like Receptor 2 Suppresses AKT Signaling and Invasive Activities of Gastric Cancer Cells by Blocking Expression of Phosphoinositide 3-Kinase Subunits.
Wang L; Yin J; Wang X; Shao M; Duan F; Wu W; Peng P; Jin J; Tang Y; Ruan Y; Sun Y; Gu J
Gastroenterology; 2016 May; 150(5):1183-1195.e16. PubMed ID: 26855187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
